Surgeon General Nominee Earned $270,000 From Supplement Company

Dr. Nicole Saphier, Donald Trump's nominee for US Surgeon General, reported substantial business income exceeding $200,000 from a company she owns that markets dietary supplements. This disclosure comes ahead of her Senate confirmation hearing, scheduled for Wednesday. The dietary supplement industry is characterized by loose regulation, and health and consumer advocates have voiced concerns regarding Saphier's record and potential conflicts of interest. Critics have drawn parallels between the marketing of some supplements and historical practices described as "snake oil." Saphier, a radiologist specializing in breast cancer at Memorial Sloan Kettering Cancer Center in New Jersey, also previously served as a contributor to Fox News. Her financial disclosure and ethics agreement were filed last week, detailing her financial interests. The specific amount of income reported from the supplement company was over $200,000, with a total business income reported at $270,000. This income stream from a company involved in a sector often scrutinized for unsubstantiated health claims and potential consumer deception has become a focal point for those reviewing her qualifications for the prominent public health role. The Senate confirmation process will likely involve scrutiny of these financial disclosures and the ethical implications of her business ventures in relation to her potential duties as Surgeon General. The role of Surgeon General involves advising the public on health matters and leading public health initiatives, making financial ties to industries with questionable oversight a significant consideration. Advocates argue that her involvement in the supplement market could undermine public trust in health guidance issued by the office. The financial disclosure document, a standard requirement for nominees, provides a detailed account of assets, liabilities, and income sources, allowing for a comprehensive review by senators and the public. Saphier's professional background as a medical doctor and media personality, combined with her entrepreneurial activities in the supplement space, presents a complex profile for confirmation. The hearing is expected to address these financial entanglements and her stance on regulating health-related products. The $270,000 figure represents her total reported business income, with a significant portion attributed to her supplement enterprise. This level of personal financial gain from a loosely regulated industry is a key area of concern for watchdog groups and policymakers evaluating her suitability for the position of the nation's top doctor.